← Back to Search

Behavioural Intervention

Early Palliative Care for Multiple Myeloma and Lymphoma

N/A
Recruiting
Led By Breffni Hannon, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0-3
A new diagnosis of multiple myeloma or at time of progression of disease necessitating a change in treatment plan, or relapsed/refractory aggressive B cell lymphomas after one prior line of therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after enrollment
Awards & highlights

Summary

This trial aims to test the effectiveness of providing early palliative care alongside usual cancer care for patients with multiple myeloma and aggressive B cell lymphoma. Patients will be split into two groups: one

Who is the study for?
This trial is for patients with multiple myeloma or aggressive B-cell lymphoma. It's designed to see if early palliative care, alongside standard cancer treatment, can improve their well-being and quality of life.
What is being tested?
The study tests whether introducing early palliative care improves outcomes like symptom management and mood compared to usual cancer care alone. Participants are randomly assigned to receive either additional early palliative care or just the standard treatment.
What are the potential side effects?
Since this trial focuses on palliative care (comfort measures), it does not involve new medications; therefore, typical drug side effects are not a concern here. The impact will be more on emotional and psychological aspects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can care for myself but may not be able to do heavy physical work.
Select...
I have a new or worsening multiple myeloma or aggressive B cell lymphoma after one treatment.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 2 months, and 3 months after enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 2 months, and 3 months after enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of early palliative care for outpatients with multiple myeloma and aggressive lymphoma
Quality of Life as measured by the FACIT-Pal
Secondary study objectives
Depression as measured by the PHQ-9
Performance status as measured by the PRFS
Satisfaction with care as measured by the FAMCARE-P16
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Early Palliative CareExperimental Treatment1 Intervention
Participants in the intervention/early palliative care arm will be invited to attend a consultation (in-person or via Microsoft Teams) in the outpatient palliative care clinic alongside ongoing care from their hematologist. The intervention will comprise of a comprehensive interdisciplinary assessment from a specialist palliative care nurse and a physician within 1 week of referral and monthly follow-up visit for 3 months. This will include an assessment of physical symptoms, psychological distress, social supports and advance care planning, as well as 24/7 telephone support between visits, community-based resources, and access to the acute palliative care unit, if required.
Group II: Usual CareActive Control1 Intervention
Participants in the usual care arm will receive care from their hematologist as usual, with referral to the outpatient palliative care clinic at the discretion of the hematologist or upon patient request

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,514 Previous Clinical Trials
500,125 Total Patients Enrolled
9 Trials studying Multiple Myeloma
259 Patients Enrolled for Multiple Myeloma
Myeloma CanadaUNKNOWN
1 Previous Clinical Trials
559 Total Patients Enrolled
1 Trials studying Multiple Myeloma
559 Patients Enrolled for Multiple Myeloma
The Leukemia and Lymphoma Society of CanadaUNKNOWN
~53 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top